StockData

Amrize vs Cemex SAB de CV

AMRZ and CX side by side, both in materials. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMRZ and CX compare

Amrize grew revenue faster over the last twelve months (3.5% versus 0.43% for Cemex SAB de CV).

Amrize keeps more of each dollar of sales as profit, with a net margin of 10.2% compared with 6.0% at Cemex SAB de CV.

Amrize pays a dividend yielding 1.6%; Cemex SAB de CV does not pay one.

Amrize scores higher on the StockData Score (10 against 5 for Cemex SAB de CV), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMRZCX
Size and price
Market cap$22.6B–
Share price$41.38$10.70
Change, 1 year−21.7%4.2%
Change, 5 years–68.8%
Beta (5Y)0.731.28
Employees19K40K
StockData Score
Total score10 (better)5
Valuation score3 (better)0
Growth score1 (better)0
Performance score23 (better)
Health score3 (better)2
Dividend score1 (better)0
Valuation
P/E18.2×–
P/S1.8×–
P/B1.8×–
EV/EBITDA10.2×–
P/FCF21.0×–
FCF yield4.8%–
Fair value$47.20–
Margin of safety12.3%–
Growth
Revenue growth (TTM)3.5% (better)0.43%
Revenue growth, 5Y average–5.0%
Net income growth (TTM)8.3% (better)2.2%
EPS growth (TTM)8.6% (better)2.3%
Profitability
Gross margin24.8%32.9% (better)
Operating margin15.5% (better)6.2%
Net margin10.2% (better)6.0%
FCF margin8.8% (better)6.4%
Return on equity9.8% (better)7.5%
Return on invested capital9.7% (better)3.0%
Financial health
Debt / equity0.460.42 (better)
Net debt / EBITDA2.001.66 (better)
Interest coverage5.3×–
Current ratio1.07 (better)0.83
Altman Z-score2.03–
Piotroski F-score47 (better)
Dividends and buybacks
Dividend yield1.6%–
Payout ratio–13.2%
Shareholder yield1.6%–
Ownership
Held by institutions47.1%3.7%
Held by insiders7.4%2.7%
Insider net buying, 12 months$10.2M (better)−$4.7M
Superinvestors holding3 (better)1
Short interest, % of float2.2%–

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.